Illumina, INC

Illumina, Inc. has completed a $300 million offering of 4.950% notes due 2029 to refinance existing debt maturing in September 2026.

Illumina, Inc. has entered into a new $1 billion senior unsecured five-year revolving credit facility, replacing its existing agreement.

Illumina, Inc. announced an offering of $300 million in 4.950% notes due 2029 to refinance existing debt maturing in September 2026.

Illumina, Inc. has entered into a settlement agreement to dismiss a shareholder lawsuit related to its GRAIL acquisition, with a court hearing scheduled for November 2, 2026.

Illumina announced strong second quarter 2026 financial results, with revenue increasing 9.5% year-over-year and raising its full-year revenue and EPS guidance.

Illumina, Inc. announced the results of its 2026 Annual Meeting of Stockholders, where all director nominees were elected and the appointment of Ernst & Young LLP as independent auditor was ratified.

Illumina Inc. announced its second quarter 2026 financial results, reporting a 9% increase in total revenue to $1.159 billion, driven by strong performance in consumables and instruments, alongside the integration of SomaLogic.

Illumina reported a slight revenue increase in Q3 2025 and a significant return to net income for the nine months ended September 28, 2025, despite ongoing macroeconomic and geopolitical challenges.

Illumina, Inc. reported a significant return to profitability in the second quarter of 2025, driven by the spin-off of GRAIL and absence of prior year's impairment charges, despite a 5% decline in total revenue.

Illumina's Q1 2025 revenue declined slightly, impacted by macroeconomic factors and challenges in China, while the company focuses on cost reduction and operational excellence.

Illumina reports a net income of $705 million for Q3 2024, driven by a gain from the reversal of a European Commission fine, despite a year-to-date net loss of $1.41 billion and a 3% revenue decrease.

Illumina's second quarter results show a significant net loss driven by goodwill and intangible asset impairments related to the GRAIL spin-off, despite a slight increase in gross profit.

Illumina's 2024 annual report reveals a slight revenue decrease, balanced by improved gross margins and the strategic spin-off of GRAIL.

Illumina's 2023 annual report details its subsidiary structure, financial performance, and strategic direction, including the planned divestiture of GRAIL.

Michael C Sullivan, Chief Commercial Officer of Illumina, Inc., reported multiple transactions in common stock on August 5, 2026.

Keith A. Meister, a Director of Illumina, Inc., sold 741,127 shares of common stock on August 4, 2026.

Scott M Davies, Chief Legal Officer of Illumina, Inc., sold 615 shares of common stock on July 30, 2026 for $200.00 per share.

Illumina, Inc. Director Keith Meister acquired 142 shares of common stock as part of his board and committee cash retainer fees for the second quarter of 2026.

Illumina Director Scott B. Ullem received 167 shares of common stock as payment for his board and committee fees for the second quarter of 2026.

Illumina Chief Legal Officer Scott M. Davies reported a transaction involving the sale of 615 shares of common stock.

Illumina, Inc. has released its proxy statement detailing the agenda for its 2026 Annual Meeting of Stockholders, including director elections, auditor ratification, and advisory vote on executive compensation.

Illumina has amended its definitive proxy statement to clarify the voting requirements and the effect of abstentions on Proposals 2, 3, and 4 for the 2025 annual meeting of stockholders.

Illumina, Inc. announces its 2025 Annual Meeting of Stockholders to be held on May 21, 2025, outlining key proposals for voting.

Illumina's proxy statement highlights a strategic refocus on its core business, board refreshment, and commitment to profitable growth in 2025.

Illumina, Inc. announces its 2024 Annual Meeting of Shareholders to be held on May 16, 2024, outlining key voting items including the election of directors and ratification of the company's independent auditor.

Illumina's proxy statement highlights board changes, responsiveness to stockholder feedback, and a goal to finalize GRAIL's divestiture by the end of the second quarter of 2024.

Capital World Investors has disclosed a beneficial ownership of 10.3% in Illumina, Inc., holding over 15.7 million shares as of March 31, 2026.

The Vanguard Group has filed an amendment to its Schedule 13G, reporting zero beneficial ownership in Illumina Inc. following an internal realignment.

Capital World Investors has reported a significant beneficial ownership stake of 13.2% in Illumina, Inc., holding over 20 million shares.

Capital World Investors has disclosed a significant passive ownership stake of 10.7% in Illumina, Inc., holding over 16.8 million shares.

Capital World Investors has filed an amended Schedule 13G, reporting a 12.1% beneficial ownership stake in Illumina, Inc. as of March 31, 2025.